PXL770 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
20	副腎白質ジストロフィー	2

20. 副腎白質ジストロフィー

臨床試験数 : 61 / 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05146284 (ClinicalTrials.gov)	December 2022	16/11/2021	Study to Assess PXL770in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystr ...	A Randomized Open-label Phase 2a Study to Assess PXL770After 12 Weeks of Treatment in Male Subjects ...	Adrenomyeloneuropathy	Drug: PXL770	Poxel SA	NULL	Not yet recruiting	18 Years	65 Years	Male	24	Phase 2	NULL
2	EUCTR2021-006223-18-DE (EUCTR)	03/05/2022	17/01/2022	Trial on patients with adrenomyeloneuropathy to assess PXL770's behaviour, a new potential medicine, ...	A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters ...	Adrenomyeloneuropathy (AMN);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PXL770 Product Code: PXL770 Other descriptive name: PXL770	Poxel S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	24	Phase 2	Germany

First Previous1Next Last